APG-2449 is a novel, orally active FAK inhibitor and a third generation ALK/ROS1 TKI that has shown potent activity against a range of ALK-resistant mutations, including G1202R, L1196M, V1180L, E1210K, S1206F, G1269A, F1174L, I1171S, and C1156Y in pre-clinical NSCLC tumor models. The gene discussed is PTK2; the disease is neoplasm.